Abstract
Gemini surfactants provide a significant opportunity in the development of new non-viral delivery systems designed for gene therapy applications. This review summarizes the wide range of gemini surfactant structures that have been employed for DNA transfection in vitro. A general observation is that those structures capable of inducing a wide variety of polymorphic structures (lamellar, hexagonal, or cubic phases) demonstrate higher transfection efficiencies. Those compounds whose structures result in pH-dependent changes in aggregate structure similarly show higher levels of transfection. In vivo transfection using gemini surfactants has been demonstrated in only three cases, and in a recent study the transfection was linked to a specific therapeutic response.
Keywords: Gene therapy, gemini surfactant, non-viral, transfection, delivery system, in vivo, in vitro
Current Gene Therapy
Title: Gemini Surfactants: A New Family of Building Blocks for Non-Viral Gene Delivery Systems
Volume: 8 Issue: 1
Author(s): Shawn D. Wettig, Ronald E. Verrall and Marianna Foldvari
Affiliation:
Keywords: Gene therapy, gemini surfactant, non-viral, transfection, delivery system, in vivo, in vitro
Abstract: Gemini surfactants provide a significant opportunity in the development of new non-viral delivery systems designed for gene therapy applications. This review summarizes the wide range of gemini surfactant structures that have been employed for DNA transfection in vitro. A general observation is that those structures capable of inducing a wide variety of polymorphic structures (lamellar, hexagonal, or cubic phases) demonstrate higher transfection efficiencies. Those compounds whose structures result in pH-dependent changes in aggregate structure similarly show higher levels of transfection. In vivo transfection using gemini surfactants has been demonstrated in only three cases, and in a recent study the transfection was linked to a specific therapeutic response.
Export Options
About this article
Cite this article as:
Wettig D. Shawn, Verrall E. Ronald and Foldvari Marianna, Gemini Surfactants: A New Family of Building Blocks for Non-Viral Gene Delivery Systems, Current Gene Therapy 2008; 8 (1) . https://dx.doi.org/10.2174/156652308783688491
DOI https://dx.doi.org/10.2174/156652308783688491 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Erectile Dysfunction as a Cardiovascular Risk Factor: Time to Step Up?
Current Vascular Pharmacology Progress in the Rational Design for Polypharmacology Drug
Current Pharmaceutical Design Rho Kinase Inhibitors: Potential Treatments for Diabetes and Diabetic Complications
Current Pharmaceutical Design On the Involvement of H2S in Nitroso Signaling and Other Mechanisms of H2S Action
Current Pharmaceutical Biotechnology Phytochemicals as Inhibitors of Candida Biofilm
Current Pharmaceutical Design Pharmacologic Modulators of Soluble Guanylate Cyclase/Cyclic Guanosine Monophosphate in the Vascular System - From Bench Top to Bedside
Current Vascular Pharmacology Immunophilin Dysfunction and Neuropathology
Current Medicinal Chemistry Current Evaluation of the Millennium Phytomedicine- Ginseng (II): Collected Chemical Entities, Modern Pharmacology, and Clinical Applications Emanated from Traditional Chinese Medicine
Current Medicinal Chemistry Guanylate Cyclase C: A Current Hot Target, from Physiology to Pathology
Current Medicinal Chemistry Anal Cancer: Focus on HIV-Positive Patients in the HAART Era
Current HIV Research Prophylaxis of Erectile Function After Radical Prostatectomy with Phosphodiesterase Type 5 Inhibitors
Current Pharmaceutical Design Potential Use of Protease Inhibitors as Vaginal and Colorectal Microbicides
Current HIV Research Sildenafil and Cardioprotection
Current Pharmaceutical Design In Vivo Beta-Cell Imaging with VMAT 2 Ligands - Current State-of-the-Art and Future Perspectives
Current Pharmaceutical Design There is a Link Between Erectile Dysfunction and Heart Failure: It could be Inflammation
Current Drug Targets Achieving Detumescence of Ischemic Priapism with Intra-Cavernosal Injection of entanyl: An Unexpected Outcome of Miscommunication Error
Current Drug Safety Effects of Obesity on Vascular Potassium Channels
Current Vascular Pharmacology Collagenolytic Enzymes and their Applications in Biomedicine
Current Medicinal Chemistry Nitric Oxide and Dietary Factors: Part V Summary/Conclusion and References
Vascular Disease Prevention (Discontinued) PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update
Current Pharmaceutical Design